BOSTON BIO SYSTEMS LTD. Intrinsic Value
BOSTON BIO SYSTEMS LTD. (BOSTONBIO) median intrinsic value is ₹8.57 from 2 valuation models (range ₹2–₹9), vs current price ₹5.39 — +59.0% upside (Trading Below Calculated Value), margin of safety 37.1%. For current market price and key ratios, visit BOSTONBIO stock price BSE.
BOSTONBIO Valuation Methods Summary — DCF, Graham Number & P/E
BOSTON BIO SYSTEMS LTD. intrinsic value across 2 models vs current price ₹5.39 — upside/downside and value range per method. Browse BOSTONBIO balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹8.57 | ₹7.71 - ₹9.43 | +59.0% | Book Value/Share: ₹8.57, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1.62 | ₹1.46 - ₹1.78 | -69.9% | Revenue/Share: ₹1.43, P/S: 0.8x |
BOSTONBIO Intrinsic Value vs Market Price — All Valuation Models
BOSTON BIO SYSTEMS LTD. fair value range ₹2–₹9 vs current market price ₹5.39 across 2 valuation models. Compare with BOSTON BIO SYSTEMS LTD. value estimation to assess whether the stock is under or overvalued.
BOSTONBIO Intrinsic Value Analysis — Undervalued or Overvalued?
BOSTON BIO SYSTEMS LTD. median intrinsic value ₹8.57, current price ₹5.39 — Trading Below Calculated Value by 59.0%, margin of safety 37.1%.
What is the intrinsic value of BOSTONBIO?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of BOSTON BIO SYSTEMS LTD. (BOSTONBIO) is ₹8.57 (median value). With the current market price of ₹5.39, this represents a +59.0% variance from our estimated fair value.
The valuation range spans from ₹1.62 to ₹8.57, indicating ₹1.62 - ₹8.57.
Is BOSTONBIO undervalued or overvalued?
Based on our multi-method analysis, BOSTON BIO SYSTEMS LTD. (BOSTONBIO) appears to be trading below calculated value by approximately 59.0%.
BOSTONBIO Financial Health — Key Ratios vs Industry Benchmarks
BOSTON BIO SYSTEMS LTD. financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.80 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.50 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -16.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -33.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.07x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BOSTONBIO Cash Flow Quality — Operating & Free Cash Flow
BOSTON BIO SYSTEMS LTD. operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |